Biosimilar Market by Product (Insulin, Monoclonal Antibodies, Erythropoietin, Granulocyte Colony-Stimulating Factor, Etanercept, Recombinant Human Growth Hormone, Teriparatide, Follitropin, Interferons, Enoxaparin Sodium, Calcitonin, and Glucagon), By Type of Manufacturing, By Indication, and By Region – Global Opportunities & Forecast, 2020-2027
1. Executive Summary
1.1. Key Market Insights
2. Introduction
2.1. Study Objectives
2.2. Market Definition
2.2.1. Market Covered
2.2.2. Regional Coverage
2.2.3. Study Years & Currency
2.3. Market Stakeholders
2.4. Key Questions this Study will Answer
2.5. GMI Research’s Approach & Methodology
2.5.1. Research Data
2.5.2. Primary Data
2.5.3. Demand Side and Supply Side Analysis
2.5.4. Market Size Estimation
2.5.5. Research Assumptions
3. Global Biosimilar Market- Overview
3.1. Introduction
3.2. Market Segmentation
3.3. Value Chain Analysis
3.4. Market Drivers
3.5. Market Restraints
3.6. Market Trends
4. Global Biosimilar Market Revenue Forecast till 2027
5. Global Biosimilar Market by Product Revenue Forecast till 2027
5.1. Insulin
5.2. Monoclonal Antibodies
5.3. Erythropoietin
5.4. Granulocyte Colony-Stimulating Factor
5.5. Etanercept
5.6. Recombinant Human Growth Hormone
5.7. Teriparatide
5.8. Follitropin
5.9. Interferons
5.10. Enoxaparin Sodium
5.11. Calcitonin
5.12. Glucagon
6. Global Biosimilar Market by Type of Manufacturing Revenue Forecast till 2027
6.1. Contract Manufacturing
6.2. In-House Manufacturing
7. Global Biosimilar Market by Indication Revenue Forecast till 2027
7.1. Chronic Diseases
7.2. Oncology
7.3. Blood Disorders
7.4. Autoimmune Diseases
7.5. Infectious Diseases
7.6. Growth Hormone Deficiency
7.7. Other Indications
8. Global Biosimilar Market by Region Forecast till 2027
8.1. North America Biosimilar Market Revenue Forecast till 2027
(Option 1: As a part of the free 25% customization)
8.1.1. North America Biosimilar Market by Product
8.1.1.1. Insulin
8.1.1.2. Monoclonal Antibodies
8.1.1.3. Erythropoietin
8.1.1.4. Granulocyte Colony-Stimulating Factor
8.1.1.5. Etanercept
8.1.1.6. Recombinant Human Growth Hormone
8.1.1.7. Teriparatide
8.1.1.8. Follitropin
8.1.1.9. Interferons
8.1.1.10. Enoxaparin Sodium
8.1.1.11. Calcitonin
8.1.1.12. Glucagon
8.1.2. North America Biosimilar Market by Type of Manufacturing
8.1.2.1. Contract Manufacturing
8.1.2.2. In-House Manufacturing
8.1.3. North America Biosimilar Market by Indication
8.1.3.1. Chronic Diseases
8.1.3.2. Oncology
8.1.3.3. Blood Disorders
8.1.3.4. Autoimmune Diseases
8.1.3.5. Infectious Diseases
8.1.3.6. Growth Hormone Deficiency
8.1.3.7. Other Indications
8.1.4. US Biosimilar Market All-Up
8.1.5. Canada Biosimilar Market All-Up
8.2. Europe Biosimilar Market Revenue Forecast till 2027
(Option 2: As a part of the free 25% customization)
8.2.1. Europe Biosimilar Market by Product
8.2.1.1. Insulin
8.2.1.2. Monoclonal Antibodies
8.2.1.3. Erythropoietin
8.2.1.4. Granulocyte Colony-Stimulating Factor
8.2.1.5. Etanercept
8.2.1.6. Recombinant Human Growth Hormone
8.2.1.7. Teriparatide
8.2.1.8. Follitropin
8.2.1.9. Interferons
8.2.1.10. Enoxaparin Sodium
8.2.1.11. Calcitonin
8.2.1.12. Glucagon
8.2.2. Europe Biosimilar Market by Type of Manufacturing
8.2.2.1. Contract Manufacturing
8.2.2.2. In-House Manufacturing
8.2.3. Europe Biosimilar Market by Indication
8.2.3.1. Chronic Diseases
8.2.3.2. Oncology
8.2.3.3. Blood Disorders
8.2.3.4. Autoimmune Diseases
8.2.3.5. Infectious Diseases
8.2.3.6. Growth Hormone Deficiency
8.2.3.7. Other Indications
8.2.4. UK Biosimilar Market All-Up
8.2.5. Germany Biosimilar Market All-Up
8.2.6. France Biosimilar Market All-Up
8.2.7. Spain Biosimilar Market All-Up
8.2.8. Rest of Europe Biosimilar Market All-Up
8.3. Asia-Pacific Biosimilar Market Revenue Forecast till 2027
(Option 3: As a part of the free 25% customization)
8.3.1. Asia-Pacific Biosimilar Market by Product
8.3.1.1. Insulin
8.3.1.2. Monoclonal Antibodies
8.3.1.3. Erythropoietin
8.3.1.4. Granulocyte Colony-Stimulating Factor
8.3.1.5. Etanercept
8.3.1.6. Recombinant Human Growth Hormone
8.3.1.7. Teriparatide
8.3.1.8. Follitropin
8.3.1.9. Interferons
8.3.1.10. Enoxaparin Sodium
8.3.1.11. Calcitonin
8.3.1.12. Glucagon
8.3.2. Asia-Pacific Biosimilar Market by Type of Manufacturing
8.3.2.1. Contract Manufacturing
8.3.2.2. In-House Manufacturing
8.3.3. Asia-Pacific Biosimilar Market by Indication
8.3.3.1. Chronic Diseases
8.3.3.2. Oncology
8.3.3.3. Blood Disorders
8.3.3.4. Autoimmune Diseases
8.3.3.5. Infectious Diseases
8.3.3.6. Growth Hormone Deficiency
8.3.3.7. Other Indications
8.3.4. China Biosimilar Market All-Up
8.3.5. India Biosimilar Market All-Up
8.3.6. Japan Biosimilar Market All-Up
8.3.7. Rest of APAC Biosimilar Market All-Up
8.4. RoW Biosimilar Market Revenue Forecast till 2027
(Option 4: As a part of the free 25% customization)
8.4.1. RoW Biosimilar Market by Product
8.4.1.1. Insulin
8.4.1.2. Monoclonal Antibodies
8.4.1.3. Erythropoietin
8.4.1.4. Granulocyte Colony-Stimulating Factor
8.4.1.5. Etanercept
8.4.1.6. Recombinant Human Growth Hormone
8.4.1.7. Teriparatide
8.4.1.8. Follitropin
8.4.1.9. Interferons
8.4.1.10. Enoxaparin Sodium
8.4.1.11. Calcitonin
8.4.1.12. Glucagon
8.4.2. RoW Biosimilar Market by Type of Manufacturing
8.4.2.1. Contract Manufacturing
8.4.2.2. In-House Manufacturing
8.4.3. RoW Biosimilar Market by Indication
8.4.3.1. Chronic Diseases
8.4.3.2. Oncology
8.4.3.3. Blood Disorders
8.4.3.4. Autoimmune Diseases
8.4.3.5. Infectious Diseases
8.4.3.6. Growth Hormone Deficiency
8.4.3.7. Other Indications
8.4.4. Brazil Biosimilar Market All-Up
8.4.5. South Africa Biosimilar Market All-Up
8.4.6. Saudi Arabia Biosimilar Market All-Up
8.4.7. UAE Biosimilar Market All-Up
8.4.8. Rest of world (remaining countries of the LAMEA region) Biosimilar Market All-Up
9. Competitive Landscape Analysis
9.1. Porter’s Five Forces Analysis
9.2. Industry – Competitive Landscape
9.3. Market Presence (Intensity Mapping)
9.4. Key Strategic Market Developments
10. Company Profiles (Option 5: Free 25% Customization - Profiles of 5 Additional Companies of your Choice)
10.1. Pfizer Inc.
10.1.1. Company Overview
10.1.2. Key Executives
10.1.3. Footprint & Employee Strength
10.1.4. Product Offerings
10.1.5. Financials
10.1.6. Key Company Developments
10.2. Sandoz International GmbH
10.2.1. Company Overview
10.2.2. Key Executives
10.2.3. Footprint & Employee Strength
10.2.4. Product Offerings
10.2.5. Financials
10.2.6. Key Company Developments
10.3. Teva Pharmaceutical Industries Ltd.
10.3.1. Company Overview
10.3.2. Key Executives
10.3.3. Footprint & Employee Strength
10.3.4. Product Offerings
10.3.5. Financials
10.3.6. Key Company Developments
10.4. Eli Lilly and Company
10.4.1. Company Overview
10.4.2. Key Executives
10.4.3. Footprint & Employee Strength
10.4.4. Product Offerings
10.4.5. Financials
10.4.6. Key Company Developments
10.5. Biocon
10.5.1. Company Overview
10.5.2. Key Executives
10.5.3. Footprint & Employee Strength
10.5.4. Product Offerings
10.5.5. Financials
10.5.6. Key Company Developments
10.6. Celltrion Healthcare Co., Ltd.
10.6.1. Company Overview
10.6.2. Key Executives
10.6.3. Footprint & Employee Strength
10.6.4. Product Offerings
10.6.5. Financials
10.6.6. Key Company Developments
10.7. Samsung Biologics
10.7.1. Company Overview
10.7.2. Key Executives
10.7.3. Footprint & Employee Strength
10.7.4. Product Offerings
10.7.5. Financials
10.7.6. Key Company Developments
10.8. Amgen Inc.
10.8.1. Company Overview
10.8.2. Key Executives
10.8.3. Footprint & Employee Strength
10.8.4. Product Offerings
10.8.5. Financials
10.8.6. Key Company Developments
10.9. Dr. Reddy’s Laboratories Ltd.
10.9.1. Company Overview
10.9.2. Key Executives
10.9.3. Footprint & Employee Strength
10.9.4. Product Offerings
10.9.5. Financials
10.9.6. Key Company Developments
10.10. Viatris Inc.
10.10.1. Company Overview
10.10.2. Key Executives
10.10.3. Footprint & Employee Strength
10.10.4. Product Offerings
10.10.5. Financials
10.10.6. Key Company Developments
11. About GMI Research
*Details on Financials might not be available in case of unlisted/private companies.
- Published Date: Feb - 2021
- Report Format: Excel/PPT
- Report Code: HM54A-00-0719
Licensing Options
Single-User License:
The report is used by the purchaser (One Individual) only
Multi-User License:Report is shared with maximum 5 users (employees) including the purchaser of the purchasing corporation only
Corporate License:
Report is shared with unlimited user (employees) of the purchasing corporation only
The report is used by the purchaser (One Individual) only
Multi-User License:Report is shared with maximum 5 users (employees) including the purchaser of the purchasing corporation only
Corporate License:
Report is shared with unlimited user (employees) of the purchasing corporation only
Biosimilar Market by Product (Insulin, Monoclonal Antibodies, Erythropoietin, Granulocyte Colony-Stimulating Factor, Etanercept, Recombinant Human Growth Hormone, Teriparatide, Follitropin, Interferons, Enoxaparin Sodium, Calcitonin, and Glucagon), By Type of Manufacturing, By Indication, and By Region – Global Opportunities & Forecast, 2020-2027
$ 4,499.00 – $ 6,649.00
Why GMI Research
